Microdosing LSD for Alzheimer’s proves safe in early human trial


New results have been published from one of the first placebo-controlled clinical trials investigating the effects of microdosing Lysergic Acid Diethylamide (LSD). This Phase 1 trial is the first step in testing whether these kinds of psychedelic microdose methods could be useful as a therapeutic approach for treating Alzheimer’s disease, and while the early data doesn’t identify significant cognitive benefits in microdosing, it certainly demonstrates the method is safe enough to proceed to larger efficacy trials.

Read full article on NewAtlas.

 

Tell people !

One Reply to “Microdosing LSD for Alzheimer’s proves safe in early human trial”

Leave a Reply

Your email address will not be published. Required fields are marked *